SPRO:NASDAQSpero Therapeutics, Inc. Analysis

Spero Therapeutics (SPRO) is trading at $2.48, just above its 200‑day SMA of $2.31 but below the 20‑day SMA of $2.70, indicating short‑term weakness within a longer‑term uptrend. The RSI of 41.6 suggests the stock is not yet oversold, while a bearish MACD histogram reinforces near‑term downside pressure. Nonetheless, the stock enjoys a substantial upside potential of roughly 61% versus downside risk of 39%, and its trailing P/E of 16.5 is well below the biotechnology industry average of 25.6, implying relative undervaluation. Recent earnings beat expectations—Q4 adjusted EPS of $0.53 versus a consensus of –$0.20 and revenue of $41.3 M surpassing estimates—has lifted sentiment, reflected in an “Extreme Greed” fear‑greed index reading of 91.09. Volatility remains high at 49% over the past 30 days, and volume is on a decreasing trend, flagging liquidity concerns.
On the fundamentals side, SPRO reports $66.8 M in revenue with a 174% growth rate, solid gross (42%) and operating (76%) margins, and a healthy ROE of 16%. However, operating cash flow is negative (‑$12.6 M) and free cash flow remains in the red (‑$4.3 M), though cash balances of $40.3 M should fund operations into 2028. The most material catalyst is the resubmitted NDA for tebipenem HBr, with the FDA’s PDUFA decision slated for June 18 2026; approval could unlock a multi‑drug‑resistant infection market and validate the current upside thesis.